Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy

NCT02852967 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT02852967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02852967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy, Tolerability, and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2016
Completion date
February 13, 2019
Enrollment
110 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque psoriasis